At Biogen, our mission is clear: we are pioneers in neuroscience. Since our founding in 1978 as one of the world’s first global biotechnology companies, Biogen has led innovative scientific research with the goal over the last decade to defeat devastating neurological diseases.
We believe that no other disease area holds as much need or as much promise for medical breakthroughs as neuroscience. Our focus on neuroscience, our deep scientific expertise and our courage to take risks make us leaders in the research and development of medicines to transform neuroscience to benefit society.
We aspire to transform patients’ lives and Biogen by making personalized & digital medicine in neuroscience a reality. Powered by data science and digital technologies, we drive solutions to advance research, clinical care, and patient empowerment. We believe that now, more than ever, biology and technology should go hand-in-hand to better meet patient needs, while enabling a shift towards more prevention-focused, affordable, and equitable care.
Biogen contributes to the communities where we live. We are committed to our employees, diversity, equity and inclusion, and environmental sustainability.
We came to Biogen to solve the unsolvable. We stay to create new possibilities and grow together. We work fearlessly and go beyond because we care deeply about making a difference and changing lives. All legitimate correspondence from a Biogen employee will come from “@biogen.com” or “@smartrecruiters.com” email accounts.
Biogen has pioneered the development of multiple sclerosis (MS) treatments for more than 25 years. We continue to innovate to advance MS treatment and improve outcomes for patients. Our research is focused on potentially transformative therapies, including the potential repair of the damage caused by MS. Our ongoing research into neurodegeneration and nerve repair will help pioneer new therapeutic solutions that may bring us closer to a cure for MS.
At the same time, we are working with leading academic institutions and MS treatment centers to advance better ways to diagnose, monitor and manage MS. We are also driving advances toward precision medicine by using new technologies to develop innovative programs and tools to better understand, measure and manage the treatment of MS. Together with our partners, we are working to enable doctors and patients to make more evidence-based, individualized treatment decisions with the goal of improving MS care.
Our innovative research collaborations merge technologies like biomarkers and wearable sensors with real-world data from routine care to generate standardized, high-quality data that may help drive personalized treatment.
We developed one of the world’s largest MS databases to investigate critical questions about this disease, including if there are potential predictors of MS progression, or if certain treatments used early enough may have potential long-term benefits for patients, such as delaying the need for walking aids and wheelchairs or slowing the deterioration of other critical functions.
The work we are doing today in MS is designed to expand our focus well-beyond treatment and is vital to helping us better understand this disease.
Therapies
Today, our industry-leading portfolio of medicines helps address the diverse needs people living with MS may have throughout their lives.
We have the most robust portfolio of MS therapies in the industry with four disease-modifying therapies and one symptomatic therapy; globally, more than one in three MS patients is currently treated with a Biogen product.
We are always working to further our understanding of MS and how to treat it. This includes applying human genetics to understand the basis of disease progression, investigating new approaches to repair damaged nerves in the central nervous system with the goal of improving pre-existing disability, and looking at ways of treating progressive forms of MS.
Below you’ll find our current investigational therapies in MS.
Investigational candidates in multiple sclerosis
Filter by
Multiple Sclerosis (MS)
Multiple Sclerosis (MS)
Multiple Sclerosis (MS)
All
All
Filed
P3
P2
P1
Phase
P1P1
P2P2
P3P3
Filed
Orelabrutinib (BTK inhibitor)
Multiple Sclerosis
MS causes the body’s immune system to attack myelin, a protective sheath covering nerve fibers. Damage to myelin “short circuits” communication between the brain, spinal cord and other areas of the body, severely impairing such neurological functions as mobility, vision and thinking. Over time, the nerves themselves can become damaged permanently.
Why we believe this investigational drug has the potential to help:
Orelabrutinib is a small molecule Bruton’s tyrosine kinase inhibitor (BTKi) that has the potential to inhibit B cell receptor signaling and effector functions, hypothesized to contribute to MS pathogenesis. In addition, BTK has been demonstrated to play a key role in the activation of myeloid cells of the immune system via another receptor of this cell (Fcγ receptor signaling (FcγRs)). This proposed dual mechanism of action is hypothesized to result in greater efficacy than inhibition of B cells alone. With its high kinase selectivity and high penetrance of the central nervous system, orelabrutinib has the potential to be a best-in-class BTK inhibitor for relapsing forms of MS and progressive forms of MS, as well as complementing our existing portfolio.
MS causes the body’s immune system to attack myelin, a protective sheath covering nerve fibers. Damage to myelin “short circuits” communication between the brain, spinal cord and other areas of the body, severely impairing such neurological functions as mobility, vision and thinking. Over time, the nerves themselves can become damaged permanently.
How this investigational therapy could help:
BIIB061 is an oral small molecule that induces growth of the cells that make myelin potentially allowing for the re-myelination and restoration of nerve communication in MS patients.
BIIB091 (BTK inhibitor)
Multiple sclerosis (MS)
MS causes the body’s immune system to attack myelin, a protective sheath covering nerve fibers. Damage to myelin “short circuits” communication between the brain, spinal cord and other areas of the body, severely impairing such neurological functions as mobility, vision and thinking. Over time, the nerves themselves can become damaged permanently.
How this investigational therapy could help:
BIIB091 selectively inhibits Burton’s tyrosine kinase (BTK), a non-receptor tyrosine kinase that regulates the development and signaling of B cells and myeloid cells hypothesized to contribute to MS pathogenesis. In addition, BTK has been demonstrated to play a key role in the activation of another cell of the immune system, the Myeloid cells via another receptor of this cell (Fcγ receptor signaling (FcγRs)).
MS causes the body’s immune system to attack myelin, a protective sheath covering nerve fibers. Damage to myelin “short circuits” communication between the brain, spinal cord and other areas of the body, severely impairing such neurological functions as mobility, vision and thinking. Over time, the nerves themselves can become damaged permanently.
Why we believe this investigational drug has the potential to help:
BIIB107 is a humanized monoclonal antibody that targets α4 integrins, which are essential for leukocyte trafficking into the brain and are an important element in pathology of MS. It’s hypothesized that BIIB107, by disrupting the interaction of α4 integrin and its ligands and therefore preventing leukocyte trafficking into the brain, has the potential to reduce inflammation and provide therapeutic benefit in MS.
Biogen conducts clinical trials in MS related to the investigational therapies in our pipeline to evaluate the efficacy and safety as potential medicines.
Deciding to participate in a clinical trial requires careful consideration. In most cases, the therapies investigated in clinical trials are not yet approved by regulatory agencies like the U.S. Food and Drug Administration (FDA). The benefits and risks of taking the treatment are not completely known. By volunteering for a clinical trial, you are helping the medical community determine whether new treatments are safe and effective.
A conversation between Dr. Mitzi Joi Williams, an MS expert and practicing neurologist based in Atlanta, GA, and Matt Winton, PhD, Senior Vice President and head of US MS Franchise at Biogen on health inequities that many MS patients experience with regards to access to care, discrimination, bias in medicine, and clinical trial representation.
Patient Services (for U.S. residents only)
If you’re living with relapsing multiple sclerosis (MS), know that you’re not alone. Biogen Support Services is here to help along the way. As soon as you’re prescribed a Biogen therapy, we can provide help with financial assistance, navigating insurance, or learning more about your therapy. We’re here to support you as you live with MS. Remember, your healthcare team is always your best source of information.
Once you’re prescribed a Biogen therapy, you can get connected to a Biogen Support Coordinator who can help answer questions you may have. They’ll provide one-on-one phone support and are ready to help you throughout treatment. They’ll help you access resources you may need, including:
Helpful information throughout your time on a Biogen therapy
Connections to financial and insurance assistance to help you access your medication
Nearby events where you can learn from experts and people living with relapsing MS
Follow-up calls, if you’re interested, to check in and see how you are doing
Please keep in mind that a doctor is always the primary resource when it comes to MS and treatment.
Important Notice:
You are now leaving Biogen’s corporate website.
We encourage you to read and evaluate terms of use, privacy, security and other similar policies of the destination site as they may differ from Biogen’s standards.
Third Party Sites
Biogen assumes no responsibility nor does it control, endorse or guarantee any aspect of your use of any third party sites. Additionally, the presence of this link does not imply the third party site's endorsement of Biogen or this website.
